159 related articles for article (PubMed ID: 23262208)
1. MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer.
Chen CH; Wang SW; Chen CW; Huang MR; Hung JS; Huang HC; Lin HH; Chen RJ; Shyu MK; Huang MC
Gynecol Oncol; 2013 Mar; 128(3):560-7. PubMed ID: 23262208
[TBL] [Abstract][Full Text] [Related]
2. Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells.
Wu X; Yan Q; Zhang Z; Du G; Wan X
Oncol Rep; 2012 May; 27(5):1488-96. PubMed ID: 22327423
[TBL] [Abstract][Full Text] [Related]
3. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
4. MUC20 promotes aggressive phenotypes of epithelial ovarian cancer cells via activation of the integrin β1 pathway.
Chen CH; Shyu MK; Wang SW; Chou CH; Huang MJ; Lin TC; Chen ST; Lin HH; Huang MC
Gynecol Oncol; 2016 Jan; 140(1):131-7. PubMed ID: 26616226
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway.
Tsai PC; Hsieh CY; Chiu CC; Wang CK; Chang LS; Lin SR
Toxicon; 2012 Oct; 60(5):734-43. PubMed ID: 22683533
[TBL] [Abstract][Full Text] [Related]
6. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
[TBL] [Abstract][Full Text] [Related]
7. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
8. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
[TBL] [Abstract][Full Text] [Related]
9. Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation.
Luwor RB; Chin X; McGeachie AB; Robinson PJ; Zhu HJ
Growth Factors; 2012 Aug; 30(4):220-9. PubMed ID: 22574813
[TBL] [Abstract][Full Text] [Related]
10. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
[TBL] [Abstract][Full Text] [Related]
11. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
12. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
[TBL] [Abstract][Full Text] [Related]
13. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
Zhang Z; Liu ZB; Ren WM; Ye XG; Zhang YY
Int J Mol Med; 2012 Oct; 30(4):856-62. PubMed ID: 22797360
[TBL] [Abstract][Full Text] [Related]
14. Stat3 activation in human endometrial and cervical cancers.
Chen CL; Hsieh FC; Lieblein JC; Brown J; Chan C; Wallace JA; Cheng G; Hall BM; Lin J
Br J Cancer; 2007 Feb; 96(4):591-9. PubMed ID: 17311011
[TBL] [Abstract][Full Text] [Related]
15. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
16. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
[TBL] [Abstract][Full Text] [Related]
17. Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis.
Oshima H; Popivanova BK; Oguma K; Kong D; Ishikawa TO; Oshima M
Cancer Sci; 2011 Apr; 102(4):713-9. PubMed ID: 21205091
[TBL] [Abstract][Full Text] [Related]
18. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
19. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
[TBL] [Abstract][Full Text] [Related]
20. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
